CD274 and triple-negative breast carcinoma: Studies have shown PD-L1 inhibition is effective treating in many malignant tumors such as non-small cell lung cancer (NSCLC) [6], renal cancer [7], triple-negative breast cancer [8] and bladder cancer [9, 10].